Expansion and Rationalization of Production and R&D Facilities
First written in FY2016. 24 of 32 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-10-14.
0 other companies' latest entry also says "Softened".
- 2026-10-14SoftenedEarnings presentation
「政府施策によるGxの数量目標への対応のための設備投資はピークアウトしており」
Gx数量目標への対応を目的とした設備投資について、拡充継続から投資ピークアウトという表現へ変化している。 - FY2026AdvancedAnnual report
「Total capital expenditures for the consolidated fiscal year were ¥4,559 million. The Company invested ¥1,774 million in manufacturing equipment for the second testing building and ¥1,196 million in manufacturing equipment for the tenth formulation building, as well as investing in the rationalization, maintenance and renewal of machinery and equipment at its API and formulation plants. In addition, 大桐製薬(中国)有限責任公司, a subsidiary, invested ¥331 million to expand its facilities.」
Capital expenditures for the fiscal year totaled ¥4,559 million, with specific investments reported for the second testing building, the tenth formulation building and facility expansion at the Chinese subsidiary. - 2026-04-10AdvancedEarnings presentation
「Capital investment 2,999 3,516 +17.2」
Capital investment increased from the same period of the previous year, indicating continued expansion of facilities. - FY2026-H1Update capital expenditure spendingAnnual report
「Cash used in investing activities was ¥2,330 million, compared with ¥5,287 million used in the same period of the previous year. This was mainly due to ¥2,088 million in expenditure for the acquisition of property, plant and equipment.」
The Company spent ¥2,088 million on the acquisition of property, plant and equipment during the interim period, continuing to expand its facilities. Acquisition expenditure decreased from ¥4,888 million in the same period of the previous year. - FY2025AdvancedAnnual report
「Total capital expenditures for the consolidated fiscal year were ¥4,544 million. The Company invested ¥833 million in manufacturing equipment for the tenth formulation building, as well as investing in the rationalization, maintenance and renewal of machinery and equipment at its API and formulation plants.」
The Company made full-year capital expenditures of ¥4,544 million, including ¥833 million for manufacturing equipment at the tenth formulation building. Its Chinese subsidiary also invested ¥228 million in expanding its facilities. - FY2025-H1AdvancedAnnual report
「Cash used in investing activities was ¥5,287 million, an increase of ¥1,671 million from the same period of the previous year. This was mainly due to ¥4,888 million in expenditure for the acquisition of property, plant and equipment associated with the expansion of production facilities.」
Expenditure for the acquisition of property, plant and equipment associated with the expansion of production facilities was ¥4,888 million, and capital expenditure-related spending increased by ¥1,671 million year on year. - FY2024AdvancedAnnual report
「Total capital expenditures for the consolidated fiscal year were ¥9,974 million. The Company invested ¥4,106 million in manufacturing equipment for the tenth formulation building and ¥2,885 million in manufacturing equipment for the Comprehensive Research Center, as well as investing in the rationalization, maintenance and renewal of machinery and equipment at its API and formulation plants.」
After completion of the tenth formulation building and the Comprehensive Research Center, ¥4,106 million and ¥2,885 million, respectively, was invested in the two facilities, bringing total full-year capital expenditures to ¥9,974 million. - FY2024-Q3AdvancedAnnual report
「The Company began construction of the tenth formulation building, a new formulation plant, in September 2022 and completed it in December 2023. With strong order intake expected to support a high utilization rate for the Phase 1 production equipment, and with further inquiries being received, the Company has begun Phase 2 construction to install manufacturing equipment on the 3 of the building's 5 floors that had not yet been equipped. To strengthen research and development activities, it also began construction of the Comprehensive Research Center in November 2022 and completed it in March 2024.」
Following completion of the tenth formulation building, the Company began Phase 2 construction to install manufacturing equipment on the 3 of its 5 floors that had not yet been equipped. The Company stated that the Comprehensive Research Center was completed in March 2024. - FY2024-Q2AdvancedAnnual report
「The Company began construction of the tenth formulation building, a new formulation plant, in September 2022 and completed it in December 2023. To strengthen research and development activities, it began construction of the Comprehensive Research Center in November 2022 and expects to complete it in March 2024. Cash used in investing activities was ¥3,616 million, an increase of ¥2,070 million from the same period of the previous year. This was mainly due to ¥3,627 million in expenditure for the acquisition of property, plant and equipment associated with the expansion of production facilities.」
The tenth formulation building was completed in December 2023, bringing the production-facility expansion plan to a specific completion stage. The Comprehensive Research Center is scheduled for completion in March 2024, and ¥3,627 million in expenditure for the acquisition of property, plant and equipment associated with the expansion of production facilities was recorded during the cumulative second quarter. - FY2024-Q1RestatedAnnual report
「The Company began construction of the tenth formulation building, a new formulation plant, in September 2022 and expects to complete it in December 2023. To strengthen research and development activities, it also began construction of the Comprehensive Research Center in November 2022 and expects to complete it in February 2024.」
The Company continued to report the expansion plan and scheduled completion dates for the tenth formulation building and the Comprehensive Research Center. - FY2023AdvancedAnnual report
「Total capital expenditures for the consolidated fiscal year were ¥7,024 million. The Company invested ¥3,186 million in manufacturing equipment for the tenth formulation building and ¥960 million in manufacturing equipment for the Comprehensive Research Center, as well as investing in the rationalization, maintenance and renewal of machinery and equipment at its API and formulation plants.」
For the tenth formulation building and the Comprehensive Research Center, the Company reported capital expenditure results of ¥3,186 million and ¥960 million, respectively, for the fiscal year, rather than planned construction and investment amounts. - FY2023-Q3RestatedAnnual report
「Against this backdrop, the Group is pursuing active sales activities while strengthening its production platform. The company began construction of Building 10, a new drug product manufacturing facility, in September 2022 and plans to complete it in November 2023. In addition, to strengthen its research and development activities, the company began construction of an Integrated Research Center in November 2022 and plans to complete it in February 2024.」
The Company continued to state, as in the previous quarter, that the tenth formulation building was scheduled for completion in November 2023 and the Comprehensive Research Center in February 2024, with no new progress reported. - FY2023-Q2AdvancedAnnual report
「Against this backdrop, the Group is pursuing active sales activities while strengthening its production platform. The company began construction of Building 10, a new drug product manufacturing facility, in September 2022 and plans to complete it in November 2023. In addition, to strengthen its research and development activities, the company began construction of an Integrated Research Center in November 2022 and plans to complete it in February 2024.」
The Company stated that construction of the tenth formulation building began in September 2022 and that construction of the Comprehensive Research Center, intended to strengthen research and development activities, began in November 2022. - FY2023-Q1AdvancedAnnual report
「Against this backdrop, the Group has been pursuing an active sales strategy while strengthening its production base. The Company began construction of the tenth formulation building, a new formulation plant, in September 2022 and expects to complete it in November 2023.」
As a new production-facility expansion plan, the Company stated that construction of the tenth formulation building would begin in September 2022 and be completed in November 2023. - FY2022AdvancedAnnual report
「Total capital expenditures for the consolidated fiscal year were ¥5,046 million. The Company invested ¥1,691 million in manufacturing equipment for the seventh API building and ¥769 million in manufacturing equipment for the fifth formulation building, as well as investing in the rationalization, maintenance and renewal of machinery and equipment at its API and formulation plants.」
Of the ¥5,046 million in total capital expenditures, ¥1,691 million was invested in manufacturing equipment for the seventh API building and ¥769 million in manufacturing equipment for the fifth formulation building, advancing the expansion and rationalization of production facilities. - FY2022-Q2AdvancedAnnual report
「This was mainly due to ¥1,454 million in expenditure for the acquisition of property, plant and equipment associated with the expansion of production facilities.」
The Company spent ¥1,454 million during the cumulative second quarter on the acquisition of property, plant and equipment associated with the expansion of production facilities. - FY2022-Q1AdvancedAnnual report
「On 29 September 2021, the Company issued its Second Series of Stock Acquisition Rights with a provision for revision of the exercise price through a third-party allotment. The specific uses of the funds to be raised are: ① construction of the Seventh API Building and installation of manufacturing equipment at the head-office plant (¥1,502,000,000); ② construction of the new Research Building, the Comprehensive Research Center, at the head office (¥2,600,000,000); and ③ expansion of packaging and manufacturing equipment at the head-office plant (¥652,851,000).」
Specific uses of the ¥4,754,851,000 in funding raised were identified for capital expenditures on the seventh API building, the new research building, the Comprehensive Research Center, and packaging and manufacturing equipment. The issue date was 29 September 2021, after the end of the quarter. - FY2021-Q3AdvancedAnnual report
「This was mainly due to a ¥469 million decrease in merchandise and finished goods, offset by increases of ¥551 million in notes and accounts receivable, ¥2,422 million in raw materials and supplies, and ¥2,251 million in property, plant and equipment, among others.」
Property, plant and equipment increased by ¥2,251 million from the end of the previous consolidated fiscal year as of the end of the third quarter of the current consolidated fiscal year, reflecting the increase in assets associated with the expansion of production facilities. - FY2021-Q2AdvancedAnnual report
「Cash used in investing activities was ¥2,238 million, an increase of ¥1,330 million from the same period of the previous year. This was mainly due to ¥2,249 million in expenditure for the acquisition of property, plant and equipment associated with the expansion of production facilities.」
Expenditure for the acquisition of property, plant and equipment associated with the expansion of production facilities was ¥2,249 million, up from ¥1,004 million in the same period of the previous year. - FY2020AdvancedAnnual report
「Total capital expenditures for the consolidated fiscal year were ¥3,850 million. The Company invested ¥1,098 million in the construction of the seventh API building and ¥654 million in manufacturing equipment for the eighth formulation building, as well as investing in the rationalization, maintenance and renewal of machinery and equipment at its API and formulation plants.」
Of the ¥3,850 million in total capital expenditures, ¥1,098 million was invested in the seventh API building and ¥654 million in manufacturing equipment for the eighth formulation building. - FY2020-Q2AdvancedAnnual report
「This was mainly due to ¥1,004 million in payments for the acquisition of property, plant and equipment associated with the expansion of production facilities.」
During the first six months, the company spent ¥1,004 million on the acquisition of property, plant and equipment associated with the expansion of production facilities. - FY2019AdvancedAnnual report
「Total capital investment during the fiscal year was ¥3,097 million. The filing company invested ¥1,384 million in constructing the Eighth Formulation Building, as well as in rationalizing and maintaining and renewing machinery and equipment at its API and formulation plants.」
The company invested ¥1,384 million in constructing the Eighth Formulation Building, bringing total capital investment for the fiscal year to ¥3,097 million. The company also disclosed a ¥2,000 million plan for highly potent formulation manufacturing equipment in the following fiscal year. - FY2019-Q2AdvancedAnnual report
「Cash used in investing activities was ¥1,712 million, a decrease of ¥292 million year on year. This was mainly due to ¥1,725 million in payments for the acquisition of property, plant and equipment associated with the expansion of production facilities.」
The company spent ¥1,725 million during the first six months on the acquisition of property, plant and equipment associated with the expansion of production facilities. It reported concrete progress in facility expansion, together with completion of the Eighth Formulation Building. - FY2019-Q1RestatedAnnual report
「The company began construction of Building 8, a new manufacturing facility for high-potency solid dosage forms, in October 2017 and plans to complete it in November 2018.」
The company reiterated its previous disclosure on the expansion of production facilities, including the Eighth Formulation Building, which was already under construction and scheduled for completion in November 2018. - FY2018AdvancedAnnual report
「Total capital investment during the fiscal year was ¥3,655 million. The filing company invested ¥1,893 million in constructing the Eighth Formulation Building, as well as in rationalizing and maintaining and renewing machinery and equipment at its API and formulation plants.」
The company invested ¥1,893 million in constructing the Eighth Formulation Building, bringing total capital investment for the fiscal year to ¥3,655 million. It is also advancing the expansion and rationalization of production facilities. - FY2018-Q2AdvancedAnnual report
「Cash used in investing activities was ¥2,004 million, an increase of ¥674 million year on year. This was mainly due to ¥1,985 million in payments for the acquisition of property, plant and equipment associated with the expansion of production facilities.」
The company spent ¥1,985 million during the first six months on the acquisition of property, plant and equipment associated with the expansion of production facilities. It also reported the start of construction of the Eighth Formulation Building, indicating progress in expanding its facilities. - FY2018-Q1AdvancedAnnual report
「Against this backdrop, the group continued to strengthen its production base and pursue active sales activities. Following the start of full-scale operation at the Highly Potent Formulation Plant, the Seventh Formulation Building, completed in December 2014, the Highly Potent R&D Center was completed in June 2017. The center develops and analyzes highly potent APIs and formulations and produces small-volume products such as clinical trial drugs. Subsequently, the company decided to construct the Eighth Formulation Building on the head-office plant site, with construction scheduled to begin in October 2017 and completion scheduled for December 2018.」
Following completion of the Highly Potent R&D Center, the company decided to construct the Eighth Formulation Building and specified the planned construction start and completion dates. - FY2017AdvancedAnnual report
「The filing company invested ¥1,523 million in constructing the Highly Potent R&D Center, as well as in rationalizing and maintaining and renewing machinery and equipment at its API and formulation plants.」
Capital investment totaled ¥3,530 million for the fiscal year, including ¥1,523 million invested in the Highly Potent R&D Center. - FY2017-Q3Cited as achievedAnnual report
「Against this backdrop, our group is strengthening its production platform and pursuing proactive sales activities, and full-scale operations began in the first quarter at the newly constructed Sixth API Building and Third API Packaging Building.」
The start of full-scale operation at the Sixth API Building and Third API Packaging Building was cited as an established production base for the third quarter. - FY2017-Q2Cited as achievedAnnual report
「The newly constructed Sixth API Building and Third API Packaging Building began full-scale operation in the first quarter.」
The start of full-scale operation at the Sixth API Building and Third API Packaging Building was cited as an established production base for the second quarter. - FY2017-Q1AdvancedAnnual report
「The newly constructed Sixth API Building and Third API Packaging Building have entered full-scale operation.」
The company reported the concrete progress of the Sixth API Building and Third API Packaging Building entering full-scale operation, after they had been identified as capital investment targets in the previous fiscal year. - FY2016First statedAnnual report
「The group continues to make capital investments aimed at expanding and rationalizing production facilities and strengthening its R&D capabilities.」
Capital investment totaled ¥3,992 million for the fiscal year, including investments in the Sixth API Building, Third API Packaging Building, Fifth Formulation Building and pharmaceutical industrialization process research building.